The immune response cascade that is triggered in response to the recognition of β-glucans, and their strong immunomodulatory characteristics, supports the potential use of β-glucans as DC-specific vaccine delivery agents and the generation of β-glucan-based neoglycoconjugate vaccines in other diseases, including PD. This evidence concerns the gene PPIB and Parkinson disease.